Dr Laura Hughes

University Position

Research Associate

Interests

My current research interests are on the role of the prefrontal cortex for voluntary and goal directed actions, and prefrontal interactions with other brain systems. I use both MEG and fMRI, along with behavioural and neuropsychological data, to investigate healthy adults and patients with neurodegenerative diseases (such as Parkinson's disease and frontotemporal dementia) and patients with brain lesions (for example due to tumors or stroke). I collaborate with James Rowe and our aim is to understand the cortical networks of the intact brain and to assess changes related to disease.

Key Publications

Publications

GABAergic modulation of beta power enhances motor adaptation in frontotemporal lobar degeneration

DOI: http://doi.org/10.1101/2024.06.28.24309636
Journal:
E-pub date: 1 Aug 2024
Authors: LE Hughes, NE Adams, M Rouse, M Naessens, AD Shaw, AG Murley, TE Cope, N Holland, D Nesbitt, D Street, DJ Whiteside, JB Rowe

Neurochemistry-enriched dynamic causal models of magnetoencephalography, using magnetic resonance spectroscopy.

DOI: http://doi.org/10.1016/j.neuroimage.2023.120193
Journal: Neuroimage
E-pub date: 1 Aug 2023
Authors: A Jafarian, LE Hughes, NE Adams, JH Lanskey, M Naessens, MA Rouse, AG Murley, KJ Friston, JB Rowe

Neurophysiological consequences of synapse loss in progressive supranuclear palsy.

DOI: http://doi.org/10.1093/brain/awac471
Journal: Brain
E-pub date: 1 Jun 2023
Authors: NE Adams, A Jafarian, A Perry, MA Rouse, AD Shaw, AG Murley, TE Cope, WR Bevan-Jones, L Passamonti, D Street, N Holland, D Nesbitt, LE Hughes, KJ Friston, JB Rowe

Neurophysiological consequences of synapse loss in progressive supranuclear palsy

DOI: http://doi.org/10.1101/2022.06.22.22276697
Journal:
E-pub date: 1 Aug 2022
Authors: N Adams, A Jafarian, A Perry, M Rouse, A Shaw, A Murley, T Cope, R Bevan-Jones, L Passamonti, D Street, N Holland, D Nesbitt, L Hughes, K Friston, J Rowe

Causal Evidence for the Multiple Demand Network in Change Detection: Auditory Mismatch Magnetoencephalography across Focal Neurodegenerative Diseases.

DOI: http://doi.org/10.1523/JNEUROSCI.1622-21.2022
Journal: J Neurosci
E-pub date: 13 Apr 2022
Authors: TE Cope, LE Hughes, HN Phillips, NE Adams, A Jafarian, D Nesbitt, M Assem, A Woolgar, J Duncan, JB Rowe

Towards accurate and unbiased imaging-based differentiation of Parkinson’s disease, progressive supranuclear palsy and corticobasal syndrome.

DOI: http://doi.org/10.1093/braincomms/fcaa051
Journal: Brain Commun
E-pub date: 1 Aug 2020
Authors: MM Correia, T Rittman, CL Barnes, IT Coyle-Gilchrist, B Ghosh, LE Hughes, JB Rowe

GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography.

DOI: http://doi.org/10.1523/JNEUROSCI.1689-19.2019
Journal: J Neurosci
E-pub date: 19 Feb 2020
Authors: NE Adams, LE Hughes, HN Phillips, AD Shaw, AG Murley, D Nesbitt, TE Cope, WR Bevan-Jones, L Passamonti, JB Rowe

Atomoxetine and citalopram alter brain network organization in Parkinson’s disease.

DOI: http://doi.org/10.1093/braincomms/fcz013
Journal: Brain Commun
E-pub date: 1 Aug 2019
Authors: RJ Borchert, T Rittman, CL Rae, L Passamonti, SP Jones, D Vatansever, P Vázquez Rodríguez, Z Ye, C Nombela, LE Hughes, TW Robbins, JB Rowe

Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia.

DOI: http://doi.org/10.1093/brain/awy176
Journal: Brain
E-pub date: 1 Aug 2018
Authors: LE Hughes, T Rittman, TW Robbins, JB Rowe

Neurophysiological signatures of Alzheimer’s disease and frontotemporal lobar degeneration: pathology versus phenotype.

DOI: http://doi.org/10.1093/brain/awy180
Journal: Brain
E-pub date: 1 Aug 2018
Authors: S Sami, N Williams, LE Hughes, TE Cope, T Rittman, ITS Coyle-Gilchrist, RN Henson, JB Rowe

Monitoring the past and choosing the future: the prefrontal cortical influences on voluntary action.

DOI: http://doi.org/10.1038/s41598-018-25127-y
Journal: Sci Rep
E-pub date: 8 May 2018
Authors: HN Phillips, TE Cope, LE Hughes, J Zhang, JB Rowe

Atomoxetine restores the response inhibition network in Parkinson’s disease.

DOI: http://doi.org/10.1093/brain/aww138
Journal: Brain
E-pub date: 31 Aug 2016
Authors: CL Rae, C Nombela, PV Rodríguez, Z Ye, LE Hughes, PS Jones, T Ham, T Rittman, I Coyle-Gilchrist, R Regenthal, BJ Sahakian, RA Barker, TW Robbins, JB Rowe

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease.

DOI: http://doi.org/10.1038/npp.2016.18
Journal: Neuropsychopharmacology
E-pub date: 1 Jul 2016
Authors: RJ Borchert, T Rittman, L Passamonti, Z Ye, S Sami, SP Jones, C Nombela, P Vázquez Rodríguez, D Vatansever, CL Rae, LE Hughes, TW Robbins, JB Rowe

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease.

DOI: http://doi.org/10.1038/npp.2016.46
Journal: Neuropsychopharmacology
E-pub date: 1 Jul 2016
Authors: RJ Borchert, T Rittman, L Passamonti, Z Ye, S Sami, SP Jones, C Nombela, PV Rodríguez, D Vatansever, CL Rae, LE Hughes, TW Robbins, JB Rowe

Dr Laura Hughes

Interests

Key Publications

Publications

GABAergic modulation of beta power enhances motor adaptation in frontotemporal lobar degeneration

Neurochemistry-enriched dynamic causal models of magnetoencephalography, using magnetic resonance spectroscopy.

Neurophysiological consequences of synapse loss in progressive supranuclear palsy.

Neurophysiological consequences of synapse loss in progressive supranuclear palsy

Causal Evidence for the Multiple Demand Network in Change Detection: Auditory Mismatch Magnetoencephalography across Focal Neurodegenerative Diseases.

Towards accurate and unbiased imaging-based differentiation of Parkinson’s disease, progressive supranuclear palsy and corticobasal syndrome.

GABA-ergic Dynamics in Human Frontotemporal Networks Confirmed by Pharmaco-Magnetoencephalography.

Atomoxetine and citalopram alter brain network organization in Parkinson’s disease.

Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia.

Neurophysiological signatures of Alzheimer’s disease and frontotemporal lobar degeneration: pathology versus phenotype.

Monitoring the past and choosing the future: the prefrontal cortical influences on voluntary action.

Atomoxetine restores the response inhibition network in Parkinson’s disease.

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease.

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson’s Disease.

Improving response inhibition systems in frontotemporal dementia with citalopram.

The val158met COMT polymorphism’s effect on atrophy in healthy aging and Parkinson’s disease.

Parkinson’s disease and dopaminergic therapy–differential effects on movement, reward and cognition.